CAR-T-клеточная терапия: преимущества и нерешенные проблемы

Родион Владимирович  Кораблев; Татьяна Викторовна  Брус; Сарнг Саналович  Пюрвеев; Дарья Евгеньевна  Передереева; Анастасия Викторовна  Баннова; Анна Валентиновна  Васильева; Алефтина Алексеевна  Кравцова

CAR-T cell therapy: advantages and unresolved problems

Rodion V. Korablev Saint Petersburg State Pediatric Medical University. 2 Lithuania, Saint Petersburg 194100 Russian Federation https://orcid.org/0009-0004-5754-8437
Tat’yana V. Brus Saint Petersburg State Pediatric Medical University. 2 Lithuania, Saint Petersburg 194100 Russian Federation
Sarng S. Pyurveev Saint Petersburg State Pediatric Medical University. 2 Lithuania, Saint Petersburg 194100 Russian Federation
Darya E. Peredereeva Saint Petersburg State Pediatric Medical University. 2 Lithuania, Saint Petersburg 194100 Russian Federation
Anastasiya V. Bannova KFU named after V.I. Vernadsky, Order of the Red Banner of Labor Medical Institute named after S.I. Georgievsky. 5/7 Lenin Blvd., Simferopol Republic of Crimea 2905051 Russian Federation
Anna V. Vasil’eva Saint Petersburg State Pediatric Medical University. 2 Lithuania, Saint Petersburg 194100 Russian Federation
Aleftina A. Kravcova Saint Petersburg State Pediatric Medical University. 2 Lithuania, Saint Petersburg 194100 Russian Federation

Keywords:

CAR-T-клеточная терапия CAR химерный антигенный рецептор антиген созревания B-клеток CD19 CAR-T cell therapy CAR chimeric antigen receptor B-cell maturation antigen CD19

Abstract

Immunotherapy is increasingly used in the treatment of malignant neoplasms. The most promising immunotherapy in the field of hematological oncology is therapy with T-cells bearing chimeric antigen receptors (CARs) on their surface, which has shown tremendous success in the treatment of refractory forms of B-lymphoblastic leukemia, B-cell lymphoma and multiple myeloma in both children and adults. However, many unresolved issues remain regarding the limited effectiveness of CAR-T cell therapy and associated side effects. The review provides brief current data on CAR-T cell products that have already been approved by regulators in different countries, as well as the main trends in the development of CAR-T products.

References

Brentjens R.J., Latouche J-B., Santos E., Marti F., Gong M.C., Lyddane C., King P.D., Larson S., Weiss M., Rivière I., Sadelain M. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279–286. https://doi.org/10.1038/nm827.

Kenderian S.S., Ruella M., Gill S., Kalos M. Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res. 2014;74:6383–6389. https://doi.org/10.1158/0008-5472.CAN-14-1530.

Fu Z., Zhou J., Chen R., Jin Y., Ni T., Qian L., Xiao C. Cluster of differentiation 19 chimeric antigen receptor T-cell therapy in pediatric acute lymphoblastic leukemia. Oncol Lett. 2020;20:36. https://doi.org/10.3892/ol.2020.11897.

Zhang P., Zhang G., Wan X. Challenges and new technologies in adoptive cell therapy. Journal of Hematology & Oncology 2023;16:97. https://doi.org/10.1186/s13045-023-01492-8.

Harris D.T., Hager M.V., Smith S.N., Cai Q., Stone J.D., Kruger P., Lever M., Dushek O., Schmitt T.M., Greenberg P.D., Kranz D.M. Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains. J Immunol. 2018;200:1088–100. https://doi.org/10.4049/jimmunol.1700236.

Ершов А.В., Демьянов Г.В., Насруллаева Д.А., Радкевич Е.Р., Долгих В.Т., Сидорова Н.В., Валиев Т.Т., Ефимова М.М., Мачнева Е.Б., Киргизов К.И., Киселевский М.В., Манасова З.Ш. Новейшие тенденции в совершенствовании CAR-Т-клеточной терапии: от лейкозов к солидным злокачественным новообразованиям. Российский журнал детской гематологии и онкологии (РЖДГиО). 2021;8:84–95.

Levine B.L., Miskin J., Wonnacott K., Keir C. Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev. 2016;4:92–101. https://doi.org/10.1016/j.omtm.2016.12.006.

McGarrity G.J., Hoyah G., Winemiller A., Andre K., Stein D., Blick G., Greenberg R.N., Kinder C., Zolopa A., Binder-Scholl G., Tebas P., June C.H., Humeau L.M., Rebello T.. Patient monitoring and follow-up in lentiviral clinical trials. J Gene Med. 2013;15:78–82. https://doi.org/10.1002/jgm.2691.

Zhao Z., Chen Y., Francisco N.M., Zhang Y., Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8:539–51. https://doi.org/10.1016/j.apsb.2018.03.001.

Shank B.R., Do B., Sevin A., Chen S.E., Neelapu S.S., Horowitz S.B. Chimeric Antigen Receptor T Cells in Hematologic Malignancies. Pharmacotherapy. 2017;37:334–45. https://doi.org/10.1002/phar.1900.

НМИЦДГОИ им. Дмитрия Рогачева, официальный сайт n.d. https://fnkc.ru/index.jsp?load=news&year=2024&month=8&id=528 (accessed December 4, 2024).

Perales M-A., Anderson L.D., Jain T., Kenderian S.S., Oluwole O.O., Shah G.L., Svoboda J., Hamadani M. Role of CD19 CAR T Cells in Second Line Large B Cell Lymphoma: Lessons from Phase 3 Trials — An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2022;28:546–59. https://doi.org/10.1016/j.jtct.2022.06.019.

Семочкин С.В. CAR T-клеточная терапия множественной миеломы по материалам конгрессов ASH-2021 и ASCO-2022. Клиническая онкогематология. 2023;16:1–13. https://doi.org/10.21320/2500-2139-2023-16-1-1-13.

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM) Blood American Society of Hematology n.d. https://ashpublications.org/blood/article/134/Supplement_1/577/426449/Results-from-CARTITUDE-1-A-Phase-1b-2-Study-of-JNJ (accessed December 3, 2024).

Tang Z., Wang X., Tang M., Wu J., Zhang J., Liu X., Gao F., Fu Y., Tang P., Li C. Overcoming the On Target Toxicity in Antibody Mediated Therapies via an Indirect Active Targeting Strategy n.d. https://doi.org/10.1002/advs.202206912.

Brudno J.N., Kochenderfer J.N. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45–55. https://doi.org/10.1016/j.blre.2018.11.002.

Wat J., Barmettler S. Hypogammaglobulinemia after Chimeric Antigen Receptor (CAR) T-cell therapy: characteristics, management, and future directions. J Allergy Clin Immunol Pract. 2022;10:460–6. https://doi.org/10.1016/j.jaip.2021.10.037.

Maalej K.M., Merhi M., Inchakalody V.P., Mestiri S., Alam M., Maccalli C., Cherif H., Uddin S., Steinhoff M., Marincola F.M., Dermime S. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22:20. https://doi.org/10.1186/s12943-023-01723-z.

Кораблев Р.В., Васильев А.Г. Неоангиогенез и опухолевый рост. Российские биомедицинские исследования. 2017;2(4):3–10.

Harrison A.J., Du X., von Scheidt B., Kershaw M.H., Slaney C.Y. Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers. Immunother Adv. 2021;1:ltab016. https://doi.org/10.1093/immadv/ltab016.

Hawkins E.R., D’Souza R.R., Klampatsa A. Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy. Biologics. 2021;15:95–105. https://doi.org/10.2147/BTT.S291768.

Pegram H.J., Purdon T.J., van Leeuwen D.G., Curran K.J., Giralt S.A., Barker J.N., Brentjens R.J. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015;29:415–22. https://doi.org/10.1038/leu.2014.215.

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System — PubMed n.d. https://pubmed.ncbi.nlm.nih.gov/29768210/ (accessed December 5, 2024).

Takeda K., Tsutsui H., Yoshimoto T., Adachi O., Yoshida N., Kishimoto T., Okamura H., Nakanishi K., Akira S. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity. 1998;8:383–390. https://doi.org/10.1016/s1074-7613(00)80543-9.

Robertson M.J., Kirkwood J.M., Logan T.F., Koch K.M., Kathman S., Kirby L.C., Bell W.N., Thurmond L.M., Weisenbach J., Dar M.M. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 2008;14:3462–9. https://doi.org/10.1158/1078-0432.CCR-07-4740.

Chohan K.L., Siegler E.L., Kenderian S.S. CAR-T Cell Therapy: the Efficacy and Toxicity Balance. Curr Hematol Malig Rep. 2023;18:9–18. https://doi.org/10.1007/s11899-023-00687-7.

Neelapu S.S. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019;37(Suppl 1):48–52. https://doi.org/10.1002/hon.2595.

Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., Chew A., Gonzalez V.E., Zheng Z., Lacey S.F., Mahnke Y.D., Melenhorst J.J., Rheingold S.R., Shen A., Teachey D.T., Levine B.L., June C.H., Porter D.L., Grupp S.A. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17. https://doi.org/10.1056/NEJMoa1407222.

Трашков А.П., Гаглоева Т.Д., Будько А.И., Петровский А.Н., Тимаева О.И., Цыган Н.В., Станжевский А.А., Васильев А.Г., Майстренко Д.Н., Сергунова К.А., Сысоев Д.С., Шатик С.В., Антуганов Д.О., Коневега А.Л. Анализ противоопухолевой активности радиофармацевтического лекарственного препарата на основе биспецифических антител к элементам опухоль-ассоциированной стромы и изотопа лютеция 177. Педиатр. 2022;13(6):35–44. DOI: 10.17816/PED13635-44.

Новиков В., Малеков Д., Субора Н., Позднякова О., Поздняков А., Силков В., Кондратьев Г., Костылев А., Васильева М., Мелашенко Т. Поражение почек при лейкозе (клинический случай). Визуализация в медицине. 2023;5(1):45–51.

Астахова А.В., Афанасьев В.В., Бабак С.В. и др. Клиническая фармакология. М.: ГЭОТАР-Медиа; 2009. EDN: QLSRON.

Lee D.W., Santomasso B.D., Locke F.L., Ghobadi A., Turtle C.J., Brudno J.N., Maus M.V., Park J.H., Mead E., Pavletic S., Go W.Y., Eldjerou L., Gardner R.A., Frey N., Curran K.J, Peggs K., Pasquini M., DiPersio J.F., van den Brink M.R.M., Komanduri K.V., Grupp S.A., Neelapu S.S. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25:625–38. https://doi.org/10.1016/j.bbmt.2018.12.758.

Gust J., Hay K.A., Hanafi L-A., Li D., Myerson D., Gonzalez-Cuyar L.F., Yeung C., Liles W.C., Wurfel M., Lopez J.A., Chen J., Chung D., Harju-Baker S., Özpolat T., Fink K.R., Riddell S.R., Maloney D.G., Turtle C.J. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017;7:1404–19. https://doi.org/10.1158/2159-8290.CD-17-0698.

Кувшинов А.Ю., Волошин С.В., Кузяева А.А., Шуваев В.А., Михалева М.А., Мартынкевич И.С., Чечеткин А.В., Бессмельцев С.С. Современные представления о car T-клеточной терапии. Вестник Гематологии. 2019;15:4–13.

Wang T., Tang Y., Cai J., Wan X., Hu S., Lu X., Xie Z., Qiao X., Jiang H., Shao J., Yang F., Ren H., Cao Q., Qian J., Zhang J., An K., Wang J., Luo C., Liang H., Miao Y., Ma Y., Wang X., Ding L., Song L., He H., Shi W., Xiao P., Yang X., Yang J., Li W., Zhu Y., Wang N., Gu L., Chen Q., Tang J., Yang J.J., Cheng C., Leung W., Chen J., Lu J., Li B., Pui C-H.. Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial. J Clin Oncol. 2023;41:1670–83. https://doi.org/10.1200/JCO.22.01214.

CAR-T cell therapy: advantages and unresolved problems. (2025). FORCIPE, 7(3), 4-15. https://forcipe.ru/article/view/6617

Download Citation

How to Cite